All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Bookmark this article
During the 2022 ASCO Annual Meeting, the ALL Hub spoke with Nicholas Short, MD Anderson Cancer Center, Houston, US. We asked, Are chemotherapy-free treatment strategies an option for patients with PH+ ALL?
Are chemotherapy-free treatment strategies an option for patients with PH+ ALL?
Short begins by discussing historic treatments for patients with PH+ ALL, their survival, and relapse rates. Short highlights the value of lower-intensity therapies than chemotherapy, which might have fewer risks of complications, and outlines modern chemotherapy-free therapies, like blinatumomab, and their response rates and high rates of MRD negativity. Finally, Short discusses the D-ALBA study and the investigation into ponatinib and blinatumomab.
Could ponatinib + blinatumomab substitute chemo + allo-HSCT as frontline therapy for Ph+ acute lymphoblastic leukemia?
During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Nicholas Short, MD Anderson Cancer Center, Houston, US. We asked, Could...
TKI maintenance therapy post-allogeneic HCT improves outcomes in patients with Ph+ ALL
A recent retrospective study published in Blood by Saini et al. compares the clinical outcomes of patients with Ph+ ALL receiving allo-HCT with and without TKI...
Subscribe to get the best content related to ALL delivered to your inbox